Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY) and RegenXBio (RGNX).
Alnylam Pharma (ALNY)
In a report released today, Leland Gershell from Oppenheimer assigned a Hold rating to Alnylam Pharma. The company’s shares closed last Wednesday at $133.36.
According to TipRanks.com, Gershell is a 3-star analyst with an average return of 2.5% and a 36.7% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.
Alnylam Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $167.36, implying a 27.5% upside from current levels. In a report issued on April 29, RBC Capital also maintained a Hold rating on the stock with a $144.00 price target.
See today’s analyst top recommended stocks >>
RegenXBio (RGNX)
Raymond James analyst Dane Leone maintained a Buy rating on RegenXBio today. The company’s shares closed last Wednesday at $34.81.
According to TipRanks.com, Leone is a 5-star analyst with an average return of 13.5% and a 60.3% success rate. Leone covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Adverum Biotechnologies, and Tarsus Pharmaceuticals.
RegenXBio has an analyst consensus of Moderate Buy, with a price target consensus of $52.75, implying a 48.7% upside from current levels. In a report issued on May 6, UBS also maintained a Buy rating on the stock with a $59.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
